An FDA advisory committee has voted to support Johnson & Johnson‘s (NYSE:JNJ) Spravato esketamine nasal spray product as a therapy for adults living with treatment-resistant depression.
J&J’s Janssen touted that if the U.S. regulatory agency decides to approve Spravato, it would be the first medicine in 30 years to sport a new mechanism of action to treat major depressive disorder.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA committee backs J&J’s nasal spray for depression appeared first on MassDevice.